<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126801</url>
  </required_header>
  <id_info>
    <org_study_id>2009p001776</org_study_id>
    <nct_id>NCT01126801</nct_id>
  </id_info>
  <brief_title>Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women</brief_title>
  <official_title>Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is a controlled study of estradiol therapy in early postmenopausal women with
      and without frequent hot flashes that will be used to determine whether hot flashes are an
      important intermediary in the generation of menopause-associated depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SPECIFIC AIMS (Research Objectives)

      To define the relative effects of hot flashes and changes in estradiol on mood in
      postmenopausal women:

      Hypotheses:

        1. Estrogen treatment has a similar therapeutic effect on mood in women with and without
           frequent hot flashes

        2. Estradiol levels correlate with improvement in mood
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped enrolling subjects due to challenge of identifying eligible participants
  </why_stopped>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of Mood, Measured by the Clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) From Baseline to Study End.</measure>
    <time_frame>one month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of Mood, Measured by the Self-rated Beck Depression Inventory (BDI) From Baseline to Study End.</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Menopausal Depression</condition>
  <arm_group>
    <arm_group_label>Estradiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>Oral estradiol 1.0 mg/day for four weeks.</description>
    <arm_group_label>Estradiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>Placebo control matched to estradiol tablets. Daily dosing for one month.</description>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women ≥40 years-old

          -  Early postmenopausal, defined as:

          -  No menstrual bleeding for 12-60 months secondary to natural menopause, according to
             STRAW criteria48

          -  Hysterectomy without bilateral oophorectomy if surgery was completed after 6+ months
             of amenorrhea (no maximum duration of amenorrhea required)

          -  Bilateral oophorectomy (no minimum or maximum duration of amenorrhea required)

          -  Serum follicle-stimulating hormone (FSH) &gt;25 IU/L and estradiol &lt;20 pg/ml

          -  Diagnosis of major depression on the MINI

          -  Mild-to-moderate depressive symptoms, as indicated by MADRS score 15-31 and BDI score
             &gt;15

          -  Normal mammogram within the past 2 years

          -  Good general health

        Exclusion Criteria:

          -  Severe depression, defined as a MADRS score &gt;31, psychotic symptoms, or suicidal or
             homicidal ideation

          -  Psychiatric illness, as defined by clinical interview and the Mini-International
             Neuropsychiatric Interview (MINI), as:

               -  A lifetime history of bipolar disorder

               -  A lifetime history of severe depression, as characterized by current or prior
                  psychotic symptoms, inpatient psychiatric hospitalization or a suicide attempt in
                  the previous 5 years, or

               -  Current panic disorder or obsessive compulsive disorder

               -  A lifetime history of psychotic symptoms

               -  Current anorexia nervosa

               -  An alcohol or substance-use disorder active within the past year

               -  Current suicidal or homicidal ideation

          -  Previous diagnosis of a sleep disorder (sleep apnea, PLMS, etc) or diagnosed on a
             screening PSG study

          -  Pregnant, confirmed with serum ß-HCG at baseline (Visit 1)

          -  Breastfeeding

          -  Contraindication, hypersensitivity, or previous adverse reaction to E2 therapy

          -  Current or recent (1 month) use of centrally active medications (antidepressants,
             anxiolytics, hypnotics, anticonvulsants, stimulants)

          -  Current or recent (2 months) use of systemic hormone medications

          -  History of breast cancer, premalignant breast lesions, or undiagnosed breast mass

          -  Vaginal spotting or bleeding

          -  History of thrombo-embolism, cardiovascular disease, congestive heart failure or other
             contraindication to estradiol therapy.

          -  Liver dysfunction or disease

          -  Renal insufficiency

          -  Contraindications to progestin therapy

          -  Asthma, diabetes mellitus, epilepsy, and migraine disorders that are not stable and
             under medical management

          -  Other medical contraindications to estradiol and progestin therapy including
             porphyria, systemic lupus erythematosus, hepatic hemangiomas, deep vein thrombosis,
             hereditary angioedema, hypertriglyceridemia, severe Hypocalcemia.

          -  Clinically significant abnormalities in screening blood tests including:

               -  Thyroid-stimulating hormone &lt;0.50 or &gt;5.0 uU/mL)

               -  Shift workers
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hadine Joffe, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2010</study_first_submitted>
  <study_first_submitted_qc>May 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2010</study_first_posted>
  <results_first_submitted>July 12, 2016</results_first_submitted>
  <results_first_submitted_qc>July 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2016</results_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Hadine Joffe, MD</investigator_full_name>
    <investigator_title>Vice Chair for Research, Psychiatry Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Estradiol</title>
          <description>Estradiol: Oral estradiol 1.0 mg/day for four weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo control: Placebo control matched to estradiol tablets. Daily dosing for one month.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Estradiol</title>
          <description>Estradiol: Oral estradiol 1.0 mg/day for four weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo control: Placebo control matched to estradiol tablets. Daily dosing for one month.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="0"/>
                    <measurement group_id="B2" value="55" spread="0"/>
                    <measurement group_id="B3" value="52.5" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement of Mood, Measured by the Clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) From Baseline to Study End.</title>
        <time_frame>one month</time_frame>
        <population>No participants were analyzed since the study was terminated due to difficulty recruiting subjects. Because data from only one subject per arm were collected, these data are not reported to preserve subject privacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Estradiol</title>
            <description>Estradiol: Oral estradiol 1.0 mg/day for four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo control: Placebo control matched to estradiol tablets. Daily dosing for one month.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Mood, Measured by the Clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) From Baseline to Study End.</title>
          <population>No participants were analyzed since the study was terminated due to difficulty recruiting subjects. Because data from only one subject per arm were collected, these data are not reported to preserve subject privacy.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Mood, Measured by the Self-rated Beck Depression Inventory (BDI) From Baseline to Study End.</title>
        <time_frame>one month</time_frame>
        <population>No participants were analyzed since the study was terminated due to difficulty recruiting subjects. Because data from only one subject per arm were collected, these data are not reported to preserve subject privacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Estradiol</title>
            <description>Estradiol: Oral estradiol 1.0 mg/day for four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo control: Placebo control matched to estradiol tablets. Daily dosing for one month.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Mood, Measured by the Self-rated Beck Depression Inventory (BDI) From Baseline to Study End.</title>
          <population>No participants were analyzed since the study was terminated due to difficulty recruiting subjects. Because data from only one subject per arm were collected, these data are not reported to preserve subject privacy.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Estradiol</title>
          <description>Estradiol: Oral estradiol 1.0 mg/day for four weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo control: Placebo control matched to estradiol tablets. Daily dosing for one month.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the challenge of identifying eligible participants, we decided to stop enrolling subjects and not to analyze the 2 completed participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Hadine Joffe</name_or_title>
      <organization>Brigham &amp; Women's Hospital</organization>
      <phone>617-732-4906</phone>
      <email>hjoffe@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

